Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company focused on developing and commercializing targeted topical therapies for chronic inflammatory skin diseases. Its primary commercial product is ZORYVE (roflumilast), a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor available in once-daily cream and foam formulations, approved in the United States and Canada for the treatment of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis across multiple age groups. The ZORYVE franchise encompasses four distinct formulations: cream 0.3%, cream 0.15%, cream 0.05%, and foam 0.3%. Arcutis has secured seven FDA approvals since 2022 and is actively expanding indications, including into pediatric and infant populations. The company's pipeline includes a Phase 2 program evaluating ZORYVE foam 0.3% for vitiligo and hidradenitis suppurativa, as well as ARQ-234, a fusion protein checkpoint agonist of the CD200 receptor currently in Phase 1a/1b trials for moderate to severe atopic dermatitis. Arcutis operates a growing dermatology-focused sales force in the United States, supplemented by digital health initiatives to improve patient access. Updated Aug 5, 2026